entertainment -WSS

entertainment

author：leisure time 2025-09-05 13:28:24 - browse：79

Colorful broken DNA helix genome. -- health coverage from STAT — Adobe

In 2020, as biotech stocks surged amid the pandemic, a startup called Taysha Gene Therapies raised over $300 million off an audacious promise: It was going to license and develop gene therapies for at least 18 different rare and serious neurological diseases.

The effort brought hope for many rare disease families, some of whom had raised money to fund the UT-Southwestern scientist who designed the treatments after they saw no other options for their children.

Last week, the grand plan took perhaps a final blow. Taysha announced it would discontinue development of a treatment for giant axonal neuropathy, or GAN, a fatal, degenerative disease known to affect fewer than 100 people worldwide. The FDA, Taysha said, had requested an additional clinical trial that would be infeasible.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： Sana to lay off nearly a third of staff, de

hotspot

focus

WSS

FDA panel signals lack of confidence in Amgen cancer drug data

Chimpanzees, like humans and whales, get menopause: Study

STAT Wunderkinds: Ruey Hu's digital tools for parsing research

Sana to lay off nearly a third of staff, de

Senate panel eyes new effort on drug shortages

FDA rejects Alnylam's heart disease treatment over insufficient data

Wikipedia

entertainment

entertainment

Hepatitis C has a cure — but many Americans still lack access to it

An exit interview with Bristol Myers Squibb CEO Giovanni Caforio

Continuity nursing helped my family in our darkest PICU moments

The pink breast cancer awareness ribbon needs a redesign

Hepatitis C has a cure — but many Americans still lack access to it

Eli Lilly to pay $200M for Beam’s stake in gene

George Santos makes 1st court appearance after pleading not guilty to 13 counts

FDA rejects Alnylam's heart disease treatment over insufficient data

In Memoriam: Notable people who died in 2023

Chemotherapy drug shortage eases slightly but still widespread

hotspot

Senate panel eyes new effort on drug shortages

VC firm General Catalyst wants to buy a health system

Senate panel eyes new effort on drug shortages

Meta's Zuckerberg and Chan on track to put $50 billion into science

The future of health care in the House

Was Amgen transparent enough on FDA's concern on cancer drug?

hotspot

Wikipedia

focus

hotspot